Novartis announces Ribociclib has been recommended by the NICE for use on the NHS in combination with fulvestrant, where exemestane plus everolimus is the most appropriate alternative, for treating women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer who have received prior endocrine therapy. Ribociclib in combination
AstraZeneca and MSD‘s Olaparib has been approved by the European Commission for the treatment of germline BRCA-mutated HER2-negative metastatic breast cancer. The approval allows for the first PARP inhibitor approved in Europe for patients with this difficult-to-treat disease, and the third EU approval for Olaparib. The European commission made the approval based on data from
US Patients will now be able to access another biosimilar version of Trastuzumab with the FDA approval of Pfizer’s Trazimera in the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Data supplied with the application supported the similarity of Trazimera to its reference
Eli Lilly’s experimental breast cancer drug, abemaciclib, has been granted a priority review by US regulators for two indications, and is now on track to be filed in Europe later in 2017.
NICE are backing controlled use of targeted breast cancer radiotherapy treatment alongside further research. The National Institute for Health and Care Excellence recently published draft guidance recommending the Intrabeam Radiotherapy System (Carl Zeiss UK) as an option for patients with early forms of breast cancer.
Novartis has announced that the FDA has granted a breakthrough therapy designation to LEE011 (ribociclib) as first line treatment in HR+/HER2- advanced breast cancer.
The Clinical Professionals Group, Europe’s leading independent pharmaceutical staffing company, raised over £200 for Breast Cancer Care on Friday 18th October, as part of Breast Cancer Awareness Month. The offices took part in a variety of ‘pink’ themed activities throughout the day, including a pink themed quiz and sponsored pink nail painting for some of
Draft guidance issued today by the regulatory body, NICE (National Institute for Health and Care Excellence), has confirmed that the NHS in England and Wales has been advised not to routinely provide Roche’s Perjeta (pertuzumab). Perjeta was submitted as a treatment for a type of advanced breast cancer, but has been found not to represent value
Novartis announced on Friday that they have received approval from US regulators for Afinitor as a treatment for advanced breast cancer. The US Food and Drug Administration (FDA) have given the thumbs up to Afinitor (everolimus) for use with Pfizer’s Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. The
In final draft guidance given yesterday, the National Institute for Health and Clinical Excellence (NICE) announced that they are not recommending Eisai’s Halaven (eribulin) for the treatment of locally-advanced or metastatic breast cancer in people whose disease has progressed after at least two chemotherapeutic regimens for advanced disease. Although the evidence shown to NICE’s independent